Skip to main content

Advertisement

Table 2 Cox models were used to estimate the effect of different anti-hypertensive therapies on infectious, inflammatory and structural outcomes

From: Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

  Infectious (N = 21,523) Inflammatory (N = 50,449) Structural (N = 42,615)
ACE-I vs Control
Model 1 (Initial Drug)
 HR 0.886 0.924 0.865
 95%CI 0.859–0.886 0.906–0.942 0.847–0.885
p <0.0001 <0.0001 <0.0001
 NNT 240 156 104
Model 2 (Drug duration)
 Est −0.0041 −0.0034 −0.031
p <0.0001 <0.0001 <0.0001
ARB vs Control
Model 1 (Initial Drug)
 HR 0.957 0.970 0.900
 95%CI 0.914–1.009 0.940–1.001 0.868–0.933
p 0.1067 0.0568 <0.0001
 NNT 637 395 140
Model 2 (Drug duration)
 Est −0.0050 −0.0033 −0.036
p <0.0001 <0.0001 <0.0001
  1. Model 1 uses the first drug prescribed and follows the incidence of diagnosis up until the patient stops taking the medication. Model 2 takes into account the duration of the treatment in order to compare to emergence of disease. Diabetic-status, Flu Vaccine and Statin use are corrected for in each analysis comparing anti-hypertensive therapy. The number needed to treat (NNT) was also calculated for ACE-I and ARB use for infectious, inflammatory or structural outcomes